Global Information
회사소개 | 문의 | 위시리스트

제토제 : 기술과 세계 시장

Antiemetics: Technologies and Global Markets

리서치사 BCC Research
발행일 2018년 07월 상품 코드 664130
페이지 정보 영문 115 Pages
가격
US $ 2,750 ₩ 3,359,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,300 ₩ 4,031,000 PDF by E-mail (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,960 ₩ 4,837,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,752 ₩ 5,805,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


제토제 : 기술과 세계 시장 Antiemetics: Technologies and Global Markets
발행일 : 2018년 07월 페이지 정보 : 영문 115 Pages

세계 제토제 시장은 2017년 41억 달러 규모에 이르렀습니다. 시장은 2022년까지 연평균 복합 성장률(CAGR) 6.5%로 성장을 지속하여 59억 달러에 이를 것으로 예측됩니다.

세계의 제토제(Antiemetics) 시장을 조사했으며, 시장 현황과 성장 예측, 약제 클래스별·용도별·지역별 동향, 시장 진출기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 서론

제2장 요약과 하이라이트

제3장 개요

  • 서론
  • 구역질의 원인과 구토
  • 위장관 폐쇄/감염/염증
  • 약물 유발성 구역질과 구토
  • 임신 유발성 구역질과 구토
  • 수술후 구역질과 구토
  • 전정기능이상
  • 구역질과 구토의 병태생리학
  • 소화관
  • 화학 수용체 발통대(CTZ)
  • 전정기관
  • 대뇌피질

제4장 시장 및 기술 배경

  • 성장 촉진요인
  • 성장 저해요인
  • 기회

제5장 약제 클래스별 시장 분석

제6장 용도별 시장 분석

제7장 지역별 시장 분석

제8장 특허 리뷰/새로운 동향

제9장 파이프라인 분석

제10장 규제 환경

제11장 기업 개요

  • ABBOTT LABORATORIES
  • Astellas Pharma Inc.
  • APHIOS CORP
  • AUROBINDO PHARMA
  • DAIICHI SANKYO COMPANY LTD
  • EISAI CO., INC.
  • GLAXOSMITHKLINE PLC
  • HELSINN HEALTHCARE SA
  • HERON THERAPEUTICS, INC.
  • KYOWA HAKKO KIRIN PHARMA, INC.
  • MERCK & CO., INC.
  • NOVARTIS AG
  • F. HOFFMANN-LA ROCHE AG
  • SANOFI AVENTIS
  • TESARO, INC
  • TEVA PHARMACEUTICAL INDUSTRIES LTD

제12장 부록 : 약어

LSH 18.07.30

List of Tables

  • Summary Table A: Global Antiemetic Drugs Market, by Drug Class, Through 2023
  • Summary Table B: Global Antiemetic Drugs Market, by Application, Through 2023
    • Table 1: Emetic Potency of Chemotherapeutic Agents
    • Table 2: Vomiting as Adverse Effect at Therapeutic Dosage
    • Table 3: Ondansetron Patent Expiration
    • Table 4: Aloxi Patent Expiration
    • Table 5: List of FDA approved Antiemetic Drugs and Indications
    • Table 6: Global Antiemetic Drugs Market, by Drug Class, Through 2023
    • Table 7: 5-HT3 Receptor Drugs
    • Table 8: FDA Approved Dopamine Antagonists
    • Table 9: Global Antiemetic Drugs Market, by Application, Through 2023
    • Table 10: Global Antiemetic Drugs Market, by Region, Through 2023
    • Table 11: Antiemetic Drug Patents
    • Table 12: Antiemetic Drug Candidates
    • Table 13: FDA Approved Drugs
    • Table 14: List of Antiemetic Drugs Approved in Japan
    • Table 15: Abbott Laboratories: Net Revenue, 2015-2017
    • Table 16: Abbott Laboratories: Net Revenue, by Segment, 2017
    • Table 17: Abbott Laboratories: Marketed Products, 2016
    • Table 18: Astellas Pharma Inc.: Net Revenue, 2015-2017
    • Table 19: Astellas Pharma Inc.: Marketed Products, 2016
    • Table 20: Aurobindo Pharma Ltd.: Net Revenue, 2015-2017
    • Table 21: Daiichi Sankyo Company Ltd.: Net Revenue, 2015-2017
    • Table 22: Eisai Co., Inc.: Net Revenue, by Region, 2014-2016
    • Table 23: Eisai Co., Inc.: Oncology Product Sales, 2014-2016
    • Table 24: GlaxoSmithKline PLC: Net Revenue, 2014-2016
    • Table 25: Heron Therapeutics Inc.: Net Revenue, 2016-2017
    • Table 26: Kyowa Hakko Kirin Pharma Inc.: Net Revenue, 2013-2017
    • Table 27: Merck & Co. Inc.: Net Revenue, 2014-2016
    • Table 28: Novartis AG: Net Revenue, 2014-2016
    • Table 29: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017
    • Table 30: Sanofi: Net Revenue, 2014-2016
    • Table 31: Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2017
    • Table 32: Teva Pharmaceutical Industries Ltd.: Net Revenue, by Segments, 2015-2017
    • Table 33: Teva Pharmaceutical Industries Ltd: Products and Services
    • Table 34: Abbreviations

List of Figures

  • Summary Figure A: Global Antiemetic Drugs Market, by Drug Class, 2017-2023
  • Summary Figure B: Global Antiemetic Drugs Market, by Application, 2017-2023
    • Figure 1: Mechanism of Chemotherapy-Induced Nausea and Vomiting
    • Figure 2: Pathophysiology of Nausea and Vomiting
    • Figure 3: Pathophysiology of Emesis
    • Figure 4: Global Antiemetic Drugs Market, by Drug Class, 2017-2023
    • Figure 5: Global Market Share of Antiemetics, by Drug Class, 2017
    • Figure 6: Global 5-HT3 Receptor Market, 2017-2023
    • Figure 7: Global NK1 Receptor Antagonist Market, 2017-2023
    • Figure 8: Global Dopamine Receptor Market, 2017-2023
    • Figure 9: Global Antihistamines Receptor Antagonist Market, 2017-2023
    • Figure 10: Global Cannabinoids Market, 2017-2023
    • Figure 11: Global Benzodiazepines Market, 2017-2023
    • Figure 12: Global Corticosteroid Market, 2017-2023
    • Figure 13: Global Anticholinergic Drugs Market, 2017-2023
    • Figure 14: Global Market Share for Antiemetics Drug, by Application, 2017
    • Figure 15: Global CINV Drugs Market, 2017-2023
    • Figure 16: Global Gastroenteritis Antiemetic Drug Market, 2017-2023
    • Figure 17: Global NVP Antiemetic Drug Market, 2017-2023
    • Figure 18: Global PONV Antiemetic Drugs Market, 2017-2023
    • Figure 19: Global Antiemetic Drugs Market, by Region, 2017-2023
    • Figure 20: North America Antiemetic Drugs Market, 2017-2023
    • Figure 21: North America Antiemetic Drugs Market, by Application, 2017-2023
    • Figure 22: Europe Antiemetic Drugs Market, 2017-2023
    • Figure 23: Europe Antiemetic Drugs Market, by Application, 2017-2023
    • Figure 24: Asia-Pacific Antiemetic Drugs Market, 2017-2023
    • Figure 25: Asia-Pacific Antiemetic Drugs Market, by Application, 2017-2023
    • Figure 26: Middle East and Africa Antiemetic Drugs Market, 2017-2023
    • Figure 27: South America Antiemetic Drugs Market, 2017-2023
    • Figure 28: Abbott Laboratories: Revenue Share, by Segment, 2017
    • Figure 29: Astellas Pharma Inc.: Revenue Share, by Segment, 2017
    • Figure 30: Aurobindo Pharma Ltd.: Revenue Share, by Segment, 2017
    • Figure 31: Daiichi Sankyo Company Ltd.: Revenue Share, by Business Segment, 2016
    • Figure 32: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2016
    • Figure 33: GlaxoSmithKline PLC: Revenue Share, by Region, 2016
    • Figure 34: Merck & Co. Inc.: Revenue Share, by Business Segment, 2016
    • Figure 35: Merck & Co. Inc.: Revenue Share, by Region, 2016
    • Figure 36: Novartis AG: Revenue Share, by Region, 2016
    • Figure 37: Novartis AG: Revenue Share, by Business Segment, 2016
    • Figure 38: F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
    • Figure 39: Sanofi: Revenue Share, by Region, 2016
    • Figure 40: Sanofi: Revenue Share, by Business Segment, 2016
    • Figure 41: Sanofi: Revenue Share, by Pharmaceuticals Segment, 2017
    • Figure 42: Tesaro, Inc.: Net Revenue, 2015-2017
    • Figure 43: Teva Pharmaceutical Industries Ltd.: Generic Medicines Segment Revenue Share, by Region, 2017

Highlights:

The global market for antiemetics reached $4.1 billion in 2017 and should reach $5.9 billion by 2022, at a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2018-2023.

The global market for 5-HT3 receptor antagonists drug reached $1.9 billion in 2017 and should reach $2.8 billion by 2022, at a CAGR of 6.5% during the forecast period of 2018-2023.

The global market for NK1 receptor antagonists drug reached $569.4 million in 2017 and should reach $842.7 million by 2022, at a CAGR of 6.8% during the forecast period of 2018-2023.

Report Scope:

The report details the antiemetic drug market. The analysis highlights current and future market potential for antiemetic drug and presents a detailed review of pipeline drugs, blockbuster drugs, and challenges to market growth. The report also examines disease burden, regulatory environment, novel technologies, and market projections to 2023. Antiemetic drug market drivers, trends and potential regional market opportunities are also covered in this report.

The report details market shares of antiemetic drug class (5-HT3 receptor antagonists, dopamine antagonists, steroid-corticosteroids, benzodiazepines, NK1 receptor antagonist, antihistamines, cannabinoids, and anticholinergic) and geographic market segmentation of overall market; global market share by applications, with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for 2017, as base year, 2018 and forecast for 2023.

Report Includes:

  • 21 data tables and 15 additional tables
  • Country specific data and analysis for United States, Canada, Mexico, France, Germany, UK, China, India, Japan, and Middle East and Africa
  • An overview about current and future market potential for antiemetic drugs with special focus on competitive environment, pipeline drugs and blockbuster drugs
  • Coverage of disease burden, regulatory environment, and novel technologies in the antiemetic drugs market
  • Detailed description about vestibular disorder and increasing demand of innovative technology for treatment
  • Exploration of the causes of emesis, usage of antiemetics and the types of products available to treat nausea and vomiting by each application segment
  • Information about the launching of new drugs in each antiemetic drug class such as 5 HT3 receptor antagonists, dopamine antagonists, NK1 receptor antagonist, and so forth
  • Detailed company profiles of major players in the market, including Abbott Laboratories, Daiichi Sankyo Company, Ltd., Merck & Co., Novartis AG, Sanofi Aventis and Teva Pharmaceutical Industries Ltd.

Table of Contents

Chapter 1: Introduction

  • Antiemetic Technologies
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Overview

  • Introduction
  • Causes of Nausea and Vomiting
    • Gastrointestinal Obstruction/Infection/Inflammation
    • Drug-Induced Nausea and Vomiting
    • Pregnancy-Induced Nausea and Vomiting
    • Post-operative Nausea and Vomiting
    • Vestibular Disorder
  • Pathophysiology of Nausea and Vomiting
    • Gastrointestinal Tract
    • Chemoreceptor Trigger Zone
    • Vestibular Apparatus
    • Cerebral Cortex

Chapter 4: Market and Technology Background

  • Drivers
    • Global Increase in Number of Pregnancies and Burden of Underlying Disease Conditions
    • Increasing in Research Grants and Funding
    • Growing Research Activity in Innovative Antiemetic Drug Therapy
    • Use of Novel Drug Deliveries to Treat Nausea and Vomiting
  • Restraints
    • Lack of Animal Models to Prove Efficacy of Antiemetics
    • Pricing Pressure Experienced by Innovators
    • Availability of Alternative Treatments
  • Opportunities
    • Disease Burden and Increasing Number of Pregnancies in Europe and Asia-Pacific
    • Vestibular Disorders
    • Emergence of Advanced Therapies
    • Patent Expiry

Chapter 5: Market Breakdown by Drug Class

  • Introduction
    • Global Antiemetic Drugs Market
    • 5-HT3 Receptor Antagonists
    • NK1 Receptor Antagonist
    • Dopamine Antagonists
    • Antihistamines (H1 Receptor Antagonists)
    • Cannabinoids
    • Benzodiazepines
    • Corticosteroids
    • Anticholinergics

Chapter 6: Market Breakdown by Application

  • Overview
    • Market Size and Forecast
  • Chemotherapy-Induced Nausea and Vomiting
    • Introduction
    • Market Size and Forecast
    • Key CINV Market Takeaways
  • Gastroenteritis
    • Market Size and Forecast
  • Nausea and Vomiting of Pregnancy (NVP)
    • Market Size and Forecast
  • Post-Operative Nausea and Vomiting
    • Market Size and Forecast

Chapter 7: Market Breakdown by Region

  • Overview
    • Market Size and Forecast
  • North America
    • Market Size and Forecast
    • United States
    • Canada
    • Mexico
  • Europe
    • Market Size and Forecast
    • United Kingdom
    • Germany
  • Asia-Pacific
    • Market Size and Forecast
    • Middle East and Africa
    • South America

Chapter 8: Patent Review/New Developments

  • Introduction

Chapter 9: Pipeline Analysis

  • Introduction
  • NK1 Receptor Antagonists

Chapter 10: Regulatory Landscape

  • Introduction
  • Regional Regulatory Landscape
    • North America
    • Europe
    • Asia-Pacific

Chapter 11: Company Profiles

  • ABBOTT LABORATORIES
    • Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
  • ASTELLAS PHARMA INC.
    • Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
  • APHIOS CORP.
    • Overview
  • AUROBINDO PHARMA
    • Overview
    • Financial Information
    • Products and Services
  • DAIICHI SANKYO COMPANY LTD.
    • Overview
    • Financial Information
    • Product and Services
    • Development and Strategies
  • EISAI CO., INC.
    • Overview
    • Financial Information
    • Products and Services
  • GLAXOSMITHKLINE PLC
    • Overview
    • Financial Information
    • Products and Services
  • HELSINN HEALTHCARE SA
    • Overview
    • Products and Services
    • Key Developments and Strategies
  • HERON THERAPEUTICS, INC.
    • Overview
    • Financials
    • Products and Services
  • IPCA LABORATORIES, LTD.
    • Overview
  • KYOWA HAKKO KIRIN PHARMA, INC.
    • Overview
    • Financials
  • MERCK & CO., INC.
    • Overview
    • Financial Information
    • Products and Services
  • NOVARTIS AG
    • Overview
    • Financial Information
  • F. HOFFMANN-LA ROCHE AG
    • Overview
    • Financial Information
    • Products and Services
  • SANOFI AVENTIS
    • Overview
    • Financial Information
    • Products and Services
  • TESARO, INC.
    • Overview
    • Financial Information
    • Products and Services
    • Development and strategies
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • Overview
    • Financial Information
    • Product and Services
    • Development and Strategies

Chapter 12: Appendix: Abbreviations

Back to Top
전화 문의
F A Q